Buproprion after ACS with disappointing results

In this trial of patients hospitalized with ACS, they were randomized to buproprion or placebo for 8 weeks (with adjunctive nursing support). The abstinence rates at 1 year were the same between the groups (31% vs 33%), and more patients in the buproprion group experienced dizziness (14% vs 1%). Buproprion is not better than placebo in reducing long term smoking rates in patients after ACS (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment